BidaskClub Downgrades Karyopharm Therapeutics (KPTI) to Sell

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday.

A number of other research analysts have also weighed in on KPTI. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Canaccord Genuity reissued a “buy” rating and set a $27.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, August 7th. Robert W. Baird reissued a “buy” rating and set a $25.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. ValuEngine lowered shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Karyopharm Therapeutics currently has an average rating of “Buy” and an average target price of $22.90.

KPTI stock opened at $10.54 on Thursday. Karyopharm Therapeutics has a 1 year low of $9.00 and a 1 year high of $21.71. The firm has a market capitalization of $660.75 million, a P/E ratio of -3.75 and a beta of 3.75.



Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.21. The business had revenue of $19.89 million during the quarter, compared to analyst estimates of $5.97 million. Research analysts forecast that Karyopharm Therapeutics will post -3.18 earnings per share for the current year.

In other news, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $19.31, for a total transaction of $241,375.00. Following the transaction, the insider now owns 726,010 shares in the company, valued at approximately $14,019,253.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ltd Chione sold 11,468 shares of the business’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $21.05, for a total transaction of $241,401.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 827,266 shares of company stock valued at $16,495,001. Company insiders own 13.26% of the company’s stock.

Large investors have recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new position in shares of Karyopharm Therapeutics during the 3rd quarter worth about $266,000. Metropolitan Life Insurance Co. NY increased its holdings in shares of Karyopharm Therapeutics by 38.9% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after purchasing an additional 4,556 shares during the period. Voya Investment Management LLC increased its holdings in shares of Karyopharm Therapeutics by 24.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after purchasing an additional 3,653 shares during the period. UBS Group AG increased its holdings in shares of Karyopharm Therapeutics by 761.8% during the 1st quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after purchasing an additional 17,354 shares during the period. Finally, California Public Employees Retirement System bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $339,000. Institutional investors own 71.84% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Further Reading: Leveraged Buyout (LBO)

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply